Investor Relations

PURE Bioscience (OTCQB: PURE) is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent that is manufactured as a liquid and delivered in various concentrations. We currently manufacture and distribute SDC-based disinfecting and sanitizing products, which are registered by the United States Environmental Protection Agency (EPA). We also manufacture and sell SDC-based formulations to manufacturers for use as a raw material ingredient in the production of personal care products. We believe our technology platform has potential application in a number of industries and we intend to focus our current resources on providing food safety solutions to the food industry

Inquiries about stock accounts, dividends or change in name or address may be directed to PURE Bioscience's stock transfer agent:

Computershare Trust Company
P.O. BOX 30170
College Station, TX 77842-3170

Overnight correspondence should be sent to:

Computershare Trust Company
211 Quality Circle, Suite 210
College Station, TX 77845

Other investor inquires may be directed to:

Peter Wulff
Chief Financial Officer / Chief Operating Officer
619-596-8600
pwulff@purebio.com

Terri MacInnis, Director of IR
Bibicoff + MacInnis, Inc.
818-379-8500
terri@bibimac.com

PURE Bioscience Common Stock is listed on OTCQB.